Background: Previous meta-analyses have shown paradoxical increased risk of bleeding and thrombotic events in patients receiving antiangiogenics (AA) that may be simply explained by the studies design included. By a meta-epidemiological approach, we aim to investigate the impact of double-blind (DB) and open-label study designs on the risks of bleeding, venous thrombotic events (VTE) and arterial thrombotic events (ATE) in cancer patients treated with AA.
Introduction
Angiogenesis plays a pivotal role in the growth, progression and metastasis of cancers. During the past decades, advances in the understanding of angiogenesis have led to the emergence of targeted therapies for the management of advanced cancer [1] . Many angiogenesis inhibitors have been developed, targeting in particular the vascular endothelial growth factor (VEGF) pathway, which plays a crucial role in tumor angiogenesis. Approved drugs include both antibodies (bevacizumab, ramucirumab, aflibercept) and tyrosine kinase inhibitors (TKIs) (sunitinib, sorafenib, axitinib, regorafenib, pazopanib, vandetanib, cediranib, imatinib) blocking the VEGF ligand or its cell receptors. Antiangiogenic (article AA) therapies are emerging as a new cornerstone for cancer treatment, greatly improving survival in advanced disease, but they carry their own particular risks [2] . These therapies are associated with substantial adverse effects, such as increased blood pressure, fistula formation, bowel perforation, and reversible posterior leuko-encephalopathy. A paradoxical vascular safety profile has been observed, as AA therapies have been associated with increased risks of both bleeding and thrombotic events [3, 4] . Bleeding, venous thrombotic events (VTE) and arterial thrombotic events (ATE) represent a major source of morbidity and mortality, particularly in the oncology setting.
Bleeding events, mainly epistaxis, are promoted by the association of angiogenesis inhibitors with chemotherapy, which induces capillary damage and thrombopenia. Bleeding is caused by the weakening of blood vessels by tumor erosion or necrosis, combined with cavitation induced by AA therapies, these adverse effects being aggravated by antithrombotic drugs [5] .
The mechanisms by which angiogenesis inhibitors may induce thrombotic events remain unclear [4] . Inhibition of the VEGF pathway leads to impairment of endothelial cell regeneration, exposure of the subendothelial basement membrane, which contains many procoagulant proteins [6] , an increase in blood viscosity and hematocrit, facilitating a prothrombotic state [7] and a decrease in the production of nitric oxide and prostacyclin, promoting thrombosis [8] . Concomitant administration of chemotherapy and angiogenesis inhibitors has a direct procoagulant effect, by stimulating monocyte and endothelial cell expression [6, 7] .
The identification of reliable drug safety signals in clinical trials faces several challenges. In the first instance, clinical trials taken separately are underpowered to assess drug safety [9] . As for the analysis of efficacy, the analysis of drug safety requires a sufficient sample size to avoid type II errors. By combining many clinical trials, meta-analyses increase statistical power and may help to avoid this problem. Nineteen previous meta-analyses of clinical trials conducted in this way showed increased risks of both bleeding and thrombosis in cancer patients receiving AA therapies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Second, only a double-blind (DB) trial design can reduce the tendency for bias in selectively reporting or diagnosing adverse events. Lack of blinding is particularly relevant with regard to subjective symptoms where participants' inclination to report certain events may be swayed by anticipation of the adverse effects potentially associated with the drug. Physicians may equally have a greater tendency to investigate, diagnose and report specific adverse events that they consider likely to be related to the particular drug intervention. Furthermore, none of the meta-analyses mentioned above took into account the impact of study design (DB or open-label) on the results concerning the safety profile of the AA therapies evaluated and did not allow full investigation of the true risks of bleeding, VTE and ATE associated with these therapies. Since the number and indications of approved VEGF inhibitors are increasing, it is crucial to recognize and document the toxicity patterns associated with these drugs to enable early and appropriate intervention.
We therefore performed a literature-based meta-analysis of all eligible randomized trials assessing AA therapies in cancer patients to investigate the impact of study design on the observed risk of paradoxical adverse effects.
Patients and methods

Literature search
We performed a systematic review of published randomized clinical trials including a direct comparison between patients treated for cancer with and without AA therapies. Only studies evaluating angiogenesis inhibitors approved for cancer treatment were analyzed. An independent review of citations from the Medline, Cochrane and ClinicalTrial.gov databases from January 2003 (first randomized clinical trial) to January 2016 was conducted. The search was extended to abstracts from major oncological meetings of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) to pinpoint relevant clinical trials. The keywords employed in our search included 'bevacizumab, aflibercept, ramucirumab, sunitinib, sorafenib, pazopanib, axitinib, cabozantinib, regorafenib, imatinib, vandetanib, cancer, phase II, phase III, randomized, clinical trial, human studies'. The search was not restricted to articles published in English or according to cancer location. To verify the completeness of our research, we compared our results with other meta-analyses already published on the subject. We reviewed every publication, and when duplicate publications were identified, the most recent report of clinical trial was included in the meta-analysis. We systematically contacted the investigators in the event of incomplete or missing data.
Study selection
Two of the authors (JCT and SL) independently evaluated studies for possible inclusion; disagreements were resolved by discussion. To be included in the meta-analysis, clinical trials had to meet all the following criteria: (i) prospective phase II or III randomized studies in patients with solid cancers (malignant blood diseases being excluded), (ii) AA therapy was given as add-on treatment of standard treatment and (iii) availability of safety data for both bleeding and thromboembolic events.
Data extraction
Data were independently extracted by two of the authors (JCT and SL). In the event of discrepancies between the reviewers, a consensus was reached by discussion. For each clinical trial, we extracted details on study characteristics (names of authors; year of publication; number of patients randomized to each group); study design (DB versus open-label); methodological qualities of the study according to the Cochrane tool, taking into account random sequence generation, concealment of the allocation sequence, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data and selective reporting [29] ; patient characteristics (mean age, gender; disease stage, cancer location); treatment information (AA class, dose, treatment schedule); bleeding and thrombotic adverse events in each group.
Vascular adverse events
The adverse drug events considered in this meta-analysis comprised the following spontaneously reported adverse events: bleeding events of all grades, grades 3-5 bleeding events, all-grade VTE and all-grade ATE. All these AEs, related or not-related to study drug were taken into account. The National Cancer Institute's common toxicity criteria (version 2.0 or 3.0) were widely used to record the events in all the clinical trials included.
Statistical analysis
The summary statistics for the effect size of AA therapies compared with control treatment, both overall and in prespecified subgroups, were generated using a fixed-effect model and the Peto odds ratio (OR) with the corresponding 95% confidence intervals (95% CIs). For each meta-analysis, statistical heterogeneity among studies was explored using Cochrane's Q statistic, study consistency being quantified by means of the I 2 statistic [30] . In the event of significant heterogeneity (P-value <0.10) with no clear explanation for this, a random-effect model was used for data analysis [31] . Sensitivity analysis based on fixed Mantel-Haenzsel ORs, to take into account trials with zero events, was used to explore the influence on effect size of the continuity correction or no continuity correction in the AA treatment arm for trials with zero events [32] .
A P-value for the association <0.05 was considered statistically significant. Combined effect estimates were calculated globally, and according to trial design (DB or open-label). Interaction was systematically tested for open-label versus DB design and was considered as significant at P < 0.10. The results of the metaanalysis are presented graphically, including the effect size expressed as OR with the corresponding 95% CI. An OR equal to 1 indicates no difference between the treatments, of <1 indicates that AA therapy is better and of >1 indicates that control (i.e. placebo or best supportive care) is better. We explored the publication bias of the studies included in the final analysis using Begg's funnel plot and Egger's test [33, 34] . Overestimation of the treatment effect, in terms of ratio of odds ratio (ROR), was determined by dividing the OR values obtained in open-label trials by those obtained in DB trials. For example, an OR ratio of 1.3 would imply that the estimates of treatment effect were enhanced by 30% in trials with an open design compared with trials with a DB design. We derived 95% CIs using robust standard errors allowing for heterogeneity between the studies included [35] . A multivariate analysis was performed to adjust for major cofounding factors. To investigate the relationship between ROR and the period when trials were carried out, we conducted a cumulative analysis of the ROR according to the date of publication. For each adverse event, we sorted studies according to their date of publication (from the oldest to the most recent one). A first estimate of the ROR was obtained by using the first 10 studies published, the remaining studies were included one by one in the analysis providing each time a new estimate of the ROR.
All statistical analyses were performed using R statistical software, version 3.3.1 with the meta packages (version 4.7).
Results
Identification of relevant studies
The search procedure identified 3612 potentially relevant clinical trials evaluating AA, of which 2831 were immediately excluded ( Figure 1) . After a review of the remaining 781 publications, 267 trials were considered eligible for inclusion in the meta-analysis. Among these, data were fully exploitable for 46 studies. We contacted the authors of the other 221 relevant trials to ask if they knew of further data which might have been published. On this basis, 120 more studies became sufficiently informative to be eligible for inclusion. Finally, 166 trials were included in the metaanalysis, yielding a total of 72 024 patients.
Description of studies
The baseline characteristics of the studies included are presented in the supplementary Table S1 , available at Annals of Oncology online. Seventy studies were phase II and 96 phase III. A DB placebo-controlled design was used in 77 trials (31 143 patients), 89 trials having an open-label design (40 881 patients). The risk of bias assessed with the Cochrane Collaboration's tools is presented in the supplementary Figure S1 , available at Annals of Oncology online. The randomization procedure (computer-generated, centralized) and the allocation concealment were suitable in the majority of trials, thus studies were classified at low risk of bias for these two items. Conversely, about half of the studies were open-label studies, without blinded evaluation by an independent adjudication committee, implying a potential evaluation bias. This explains why the majority of trials were classified as high risk of bias. Finally, almost all the studies were considered as low risk of selective reporting bias [29] .
Between-study heterogeneity for all AE was significant. Sources of heterogeneity were not identified, even after investigating the design of the studies (open-label versus DB studies), the type of antibodies and TKIs. Thus, a random effects model was used to estimate the overall effect of treatment.
Bleeding events
All-grade bleeding events were documented in 151 of the 166 studies, and occurred in 7592 of 67 887 patients, yielding an overall incidence of 1.70% (95% CI 1.45-1.97). A significant increase in the risk of all-grade bleeding events was observed in the AA therapy group compared with the control group (OR 2.4, 95% CI 2.12-2.73; P < 0.001; random-effect model) (Figure 2) . A funnel plot to detect publication bias is provided in the supplementary Figure S2 , available at Annals of Oncology online. The funnel plot suggests possible missing small studies in the left of the plot, broadly in the white area of nonsignificance, making publication bias plausible. However, the bias apparently concerns open-label as well as DB trials, suggesting that asymmetry was not related to the design of the missing trials. Analysis by study design showed an OR for bleeding of 3.18 (95% CI 2.65-3.81) for open-label studies and 1.89 (95% CI 1.63-2.19) for DB studies (Figure 2 ). The ratio of these two ORs summarizes the association between the study design used and the magnitude of the treatment effect. The ROR was equal to 1.68 (95% CI 1.33-2.13) and indicates that the use of open-label designs was associated with a 68% increase in the estimation of major bleeding risk under AA therapy, compared with DB trials (interaction test, P < 0.001) (Figure 2 ). Analysis by AA pharmacological class showed an overestimation for both antibodies (ROR 1.45, 95% CI 1.16-1.82; interaction test, P ¼ 0.001) and TKI (ROR 1.63, 95% CI 0.81-3.30; interaction test, P ¼ 0.173).
With regard to high-grade bleeding events (grades 3-4), a significant increase in the risk of these events was observed in the AA therapy group compared with the control group (OR 1.72, 95% CI 1.50-1.99; P < 0.001; random-effect model) (Figure 2) . A funnel plot to detect a potential publication bias is provided in the supplementary Figure S3 , available at Annals of Oncology online. The funnel plot shows no apparent asymmetry, with studies with high precision plotted near the average, and studies with low precision spread evenly on both sides of the average, suggesting that publication bias is unlikely.
Analysis by study design showed a higher OR for high-grade bleeding in open-label trials (OR ¼ 2.06, 95% CI 1.67-2.55) compared with DB trials (OR ¼ 1.54, 95% CI 1.28-1.86) (Figure 2 ). The ROR was equal to 1.34 (95% CI 1.00-1.78; interaction test, P ¼ 0.044) (Figure 2 ). Analysis by AA pharmacological class revealed overestimation for both antibodies (ROR 1.32, 95% CI 0.96-1.81; interaction test, P ¼ 0.080) and TKI (ROR 1.12, 95% CI 0.51-2.49; interaction test, P ¼ 0.786). Sensitivity analyses for bleeding events, based on fixed Mantel-Haenzsel ORs to take into account trials with zero events, confirmed these results (data not shown). A significant increase in the risk of VTE was observed in the AA group compared with the control group (OR 1.19, 95% CI 1.04-1.35; P ¼ 0.0115; random-effect model) (Figure 3 ). The same result was observed using fixed Mantel-Haenzsel OR (data not shown). The funnel plot showed no apparent publication bias (see supplementary Figure S4 , available at Annals of Oncology online). With regard to study design, the OR for VTE was 1.51 (95% CI 1.26-1.81) for open-label studies and 0.99 (95% CI 0.83-1.17) for DB studies (Figure 3) . Overall, estimation of the risk of VTE under AA therapy in open studies is associated with an exaggeration of 53% (ROR 1.53, 95% CI 1.19-1.96) compared with DB trials (interaction test, P < 0.001) (Figure 3 ). Analysis by AA pharmacological class revealed overestimation for both antibodies (ROR 1.65, 95% CI 1.25-2.16; interaction test, P < 0.001) and TKI (ROR 1.32, 95% CI 0.52-3.35; interaction test, P ¼ 0.56).
Venous thrombotic events
Arterial thrombotic events
ATE were reported in 90 of the 166 studies, and occurred in 664 of 44 603 patients included, yielding an incidence of 1.53% (1.27-1.81). A significant increase in the risk of ATE was observed in patients assigned to the AA group compared with the control group (OR 1.59, 95% CI 1.30-1.94; P < 0.001; random-effect model) (Figure 3 ). The use of fixed Mantel-Haenzsel OR gives the same result (data not shown). No publication bias is suspected when To examine the temporal trends of ROR, we performed a cumulative meta-analysis (Figure 4) . For all-grade bleeding events, ROR did not seem to be time dependent. Concerning high-grade bleeding events, the ROR was greater for the first trials (from 2007 to 2010) and then decreased and remained constant between 2011 and 2016. The temporal trend of ROR concerning thrombotic events was different from the one of bleeding events. Indeed, for thrombotic events, the ROR seemed lower for the early trials with a value closed to 1. For all the AE, the ROR estimates were stable after 2011.
Discussion
Our meta-analysis shows that the estimation of adverse drug events in randomized clinical trials may be influenced by knowledge of treatment allocation. Figure 2 . Forest plots of the incidence of all-grade and high-grade bleeding events by antiangiogenic class. TKI, tyrosine kinase inhibitor; OR, odds ratio; ROR, ratio of odds ratio. may lead to exaggeration of the increase in the risks of bleeding, VTE and ATE with AA treatment by 68% (95% CI 33% to 113%), 53% (95% CI 19% to 96%), 65% (95% CI 13% to 143%), respectively, compared with use of a DB design. This overestimation may involve a risk that actually exists, as for bleedings and ATE, for which we observed a significantly increased risk when considering only DB trials. It may also lead to the estimation of an artifactual risk that is not observed in DB trials. This was the case for VTE, with a significantly increased risk in open-label studies, a risk not found when considering only DB trials. This result may be relevant for assessing the potential safety issues of new treatments evaluated in randomized, controlled trials.
Several authors have investigated the potential biases introduced by study design on treatment effects [36] [37] [38] [39] . They revealed a differential assessment of outcomes in open-label studies but did not investigate the interaction of study design with adverse event reporting. This meta-epidemiological study shows a significant overestimation of the risk of certain safety events in open-label studies compared with DB studies. In the assessment of safety data, outcome reporting bias has also been identified as a major issue [40] . This issue is probably aggravated in open-label trials when the safety data are generated by spontaneous reporting of adverse effects rather than by the occurrence of prespecified safety endpoints. This risk of reporting bias is likely to be higher for all-grade adverse events than for serious adverse events, which are reported more systematically [9, 41] . We observed a greater exaggeration for all-grade bleeding compared with high-grade bleeding in open-label studies. A higher rate of reporting of lowgrade events (such as epistaxis) may explain this difference in open-label studies. Unfortunately, with regard to adverse events, it is unlikely that the presence of an independent adjudication committee, unaware of the treatment assignment, will protect the study from this bias, as the committee mainly adjudicates events notified by the investigator. Figure 3 . Forest plots of the incidence of venous and arterial thrombotic events by antiangiogenic class. TKI, tyrosine kinase inhibitor; OR, odds ratio; ROR, ratio of odds ratio.
We endeavored to search for potential biases that could affect the results of this meta-epidemiological study. First, we made a particular effort to document all information available for the studies by contacting 120 of the 166 authors. Second, despite the lack of small studies in the left-hand section of the funnel plot of bleeding events, there were as many open-label trials as DB trials missing which consequently did not change our results. Third, we used the Peto fixed-effect model which may provide the best confidence interval coverage, and is more powerful and relatively less biased than random-effect analysis when dealing with low event rates [32] . The assessment of statistical heterogeneity is appropriate but of lesser concern when dealing with rare but serious adverse events, where the primary focus is on detecting a safety signal if present. Finally, all sensitivity analyses based on fixed Mantel-Haenzsel ORs, to take into account trials with zero events, confirmed the overall conclusions. We therefore consider that our conclusions are of value in view of the approach used for this meta-epidemiological analysis.
The risk of AA-associated bleeding events may have been overestimated by previous meta-analyses, which showed an increased risk of all-grade bleeding [18, [20] [21] [22] [23] . However, even if overestimated, this increased risk was still found when we focused on DB studies alone, for angiogenesis inhibitors of the antibody class, with an OR of 1.89 (95% CI 1.63-2.19), and to a lesser extent for TKI (OR 1.46, 95% CI 1.12-1.91). This increased risk is not trivial considering the high frequency of bleeding events in the absence of AA therapy [42] . However, for VTE, we detected no significant increase in risk with either antibodies or TKI when considering only DB trials. This crucial result challenges the conclusions of previous meta-analyses that seem to prove an increase in VTE risk with AA therapy [14, 19, 20] . This result is clinically relevant, especially as, in contrast to bleeding, diagnosis of VTE requires para-clinical examinations. Regarding ATE, previous metaanalyses highlighted the increased risk of this adverse event with both antibodies [26, 27] and TKI [10, 24] . In our study, the interaction test between DB and open-label trials was not significant for TKI and did not allow a separate analysis between open and DB trials. This observation may result from a lack of power of the studies included in the subgroup analysis (fewer than 6000 patients, compared with over 30 000 patients for the other endpoints, or for antibodies). Based on the results concerning AA antibodies from DB trials alone, an increased risk of ATE has not been demonstrated. Further data are needed to draw any conclusion on this adverse event for either antibodies or TKI. This meta-analysis allows specification of the toxicity profile of AA, providing more precise knowledge of the vascular adverse events related to AA. The benefit/risk ratio of AA therapy should therefore no longer be systematically downgraded by the risk of VTE (or of ATE in the case of AA antibodies specifically).
Conclusions
Our meta-analysis showed a significant interaction of study design on safety outcomes associated with the use of AA. Openlabel trial design may lead to an overestimation of an exiting risk of adverse drug effects, or even detect which do not exist. For more accurate estimates of safety outcomes, meta-analyses should be restricted to studies with a low risk of bias.
